Form 4: Autonomix Medical Director Reports Acquisition of Derivative Securities

David Andrew Robins, a director of Autonomix Medical, Inc., reported the acquisition of derivative securities, specifically warrants, on June 18, 2024.

Summary

• David Andrew Robins, a director of Autonomix Medical, Inc., filed a Form 4 on July 26, 2024, reporting changes in beneficial ownership.
• The earliest transaction date reported was June 18, 2024.
• Robins acquired warrants (rights to buy) for 103,990 shares of common stock at a price of $0.001 per share.
• Following the reported transaction, Robins beneficially owns 110,240 derivative securities indirectly.
• These warrants are part of a larger holding by Impulse Medical, Inc., in which Mr. Robins has an indirect interest.
• The shares underlying the warrants are subject to lockup agreements expiring six and twelve months after January 29, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard regulatory filing reporting a transaction. The acquisition of warrants by a director could be interpreted as a slightly positive signal, but the low exercise price tempers this.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of warrants, which could be seen as a positive sign of confidence in the company's future prospects, although the warrants were acquired at a very low price.

Stakeholder Impact

• The acquisition of warrants by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Form 4, Beneficial Ownership, Derivative Securities, Warrants, Autonomix Medical, AMIX, Director, Robins